Log in to your Inderes Free account to see all free content on this page.
Gabather
0.18
SEK
+23.29 %
GABA
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Less than 1K followers
+23.29%
-55%
-55%
-68.75%
-73.45%
-83.01%
-95.94%
-97.01%
-98.87%
Gabather is a pharmaceutical company. Today, there is a business focus on developing drug candidates for the treatment of nerve diseases. Particular focus is on the stimulation of gamma-aminobutyric acid, which is the main inhibitory neurotransmitter in the brain. The drug candidates are today patented on a global level. Gabather was established in 2014 and is headquartered in Malmö.
Read moreMarket cap
4.27M SEK
Turnover
48.51K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Financial calendar
21.2.
2025
Annual report '24
21.2.
2025
Extraordinary general meeting '25
28.5.
2025
Interim report Q1'25
ShowingAll content types
Gabather AB: Gabather Joins Forces with the Centre for Neuropsychiatric Schizophrenia Research in Denmark to Conduct a Clinical Phase II Study with GT-002
Gabather AB: Gabather files two new patent applications to secure novel findings on the effects of GT-002 for the treatment of psychiatric disorders
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio